TibaRay develops ultra-fast and ultra-precise technology aimed at improving radiotherapy for cancer treatment. Self-described as a significant technological advancement in the field.

TibaRay

Isoray Inc. develops innovative, personalized brachytherapy products that effectively treat many forms of cancer, focusing primarily on prostate cancer treatment.

Isoray Inc.

Leo Cancer Care is committed to challenging the conventions of radiotherapy by reintroducing the practice of treating patients in an upright position, providing an improved patient experience and products designed for economies of the future.

Leo Cancer Care

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Maxwell Becton

Fairleigh Dickinson

Becton, Dickinson and Company

TibaRay develops ultra-fast and ultra-precise technology for cancer radiotherapy. It aims to improve treatment effectiveness and reduce collateral damage to normal tissues, self-described as a significant technological advancement in the field.

TibaRay, Inc | 463 followers on LinkedIn. Bring the hope of cure to patients with cancer worldwide by creating revolutionary, ultra-fast, ultra-precise technology | TibaRay, Inc. is a dynamic, Bay Area startup developing the next generation particle-accelerator-based system for treating cancer.

Rebecca Fahrig

Jeff Amacker

President & CEO of Gonsalves & Stronck Construction Company, Inc. Emerging Tech Investor

William Stronck

PhD in Physics

Gerard Lawler

TibaRay, Inc

🌟 We’re thrilled to announce that our CEO Jeff Amacker has been invited to present TibaRay, Inc and our groundbreaking PHASER technology at the #LSIEurope24 : Emerging Medtech Summit from September 16th to 20th in Sintra, Portugal! TibaRay is developing a Radiation Therapy device that will Cure Cancer in a FLASH! LSI is a premier event, where industry visionaries, thought leaders, and professionals come together to shape the future of Medtech. 🚀 #LSIEUROPE24 #LSIalumni #medtech #radiationtherapy #fundraising Kelly Williams Blake Matrone

Following the announcement of our groundbreaking partnership with Leo Cancer Care our CEOs sat down at #PTCOG62 . Jeff Amacker and Stephen Towe discuss the cutting-edge technology and vision behind this transformative project. This collaboration promises to revolutionize radiation therapy, enhancing patient comfort and treatment effectiveness. Stay tuned for more updates as we embark on this journey to improve patient care and advance medical technology! Watch the full interview here: https://lnkd.in/eU4tG5tF #HealthcareInnovation #RadiationTherapy #Partnership #MedicalTechnology #PatientCare

Bill Loo , Board Member and co Founder talks about the benefits of #FLASH and #Upright #Radiotherapy at The 62nd Particle Therapy Co-Operative Group Conference in #Singapore #PTCOG62 . We are excited about our partnership with Leo Cancer Care and the development of this novel technology. https://lnkd.in/e5zhCM5k

Exciting news! Our company profile is now live on Fundable ! TibaRay is featured in the "New and Noteworthy" section, ensuring optimal visibility for their investor audience. We have been given the go ahead with sharing our profile with our network using the following link: https://lnkd.in/eTTRfEuj #funding #radiationtherapy #fundraising

We are beyond excited to share the unique partnership agreement signed with upright radiotherapy specialists Leo Cancer Care that will see the development of a first-of-its-kind upright linear accelerator. We are joining forces to develop a solution for photon therapy combining TibaRay’s linear accelerator (linac) technology with Leo Cancer Care’s upright patient positioning* and imaging system. The proposed partnership would involve using TibaRay’s efficient X-ray generation system as part of Leo’s future upright photon therapy solutions. CEO Jeff Amacker said: “This collaboration aims to leverage the technological strengths of both companies to jointly develop innovative new products that will set new industry standards in Radiation Therapy and drive growth for our organisations. “TibaRay has breakthrough technology and know-how in X-ray generation and Radiation Therapy systems and we have been impressed with Leo Cancer Care’s expertise in upright radiotherapy solutions. “By combining our respective strengths, we believe we can create unique products that will change the face of Radiation Therapy for good and bring hope of cure to patients with cancer globally. This is a shared vision of both TibaRay and Leo Cancer Care that we are excited to realize together.” Leo Cancer Care CEO Stephen Towe said: “Collaborations such as this illustrate how our simple shift from machine rotation to patient rotation provides a platform for new and innovative modalities. We believe our solutions firmly belong in the future of cancer care, working with our friends TibaRay the future of upright radiotherapy looks even brighter.” With the agreement, the companies have a product development roadmap and will work closely and cohesively to deliver better treatment options to patients. Leo Board Chairman Thomas (Rock) Mackie , who as a long-standing innovator in the world of radiation technology, played a pivotal role in forging the partnership, added: "Leo Cancer Care is looking forward to offering the advantages of the TibaRay accelerator. The TibaRay accelerator will deliver a higher photon beam output in a more compact footprint combined with faster upright position setup times. This will facilitate a more human patient experience and improve patient access to care.” Founder and Board Director, Bill Loo , a physician-scientist Radiation Oncologist and Bioengineer, and Director of Thoracic Radiation Oncology and New Technologies at Stanford Cancer Institute , added: “The novel combination of technologies enabling extremely rapid dose delivery and upright patient positioning promises not only a leap in precision targeted radiotherapy for cancer, but also better accessibility and clinical efficiency of curative cancer treatment for patients worldwide.” #radiationtherapy #uprightlinearaccelerator #collaboration

TibaRay, Inc is on a mission to cure cancer with its technology. Supported by Keiretsu Forum Members, they’re showcasing at the Angel Capital Association Summit. Come see how we're backing solutions that promise a better tomorrow.

Howard Lubert

Excited to share that TibaRay has been invited to pitch at Keiretsu Forum London on Monday 29th of April. CEO Jeff Amacker will be presenting the opportunity to invest in our Radiation Therapy device. TibaRay is presenting among 2 other companies MatLogica and Biostress and TO THE MARKET (Keiretsu portfolio company) will be sharing their exciting progress.

🌟We are excited and proud to share the founders of TibaRay🌟 Rebecca Fahrig PhD Head of Business Line EVR (Endovascular Robotics) for Business Area Advanced Therapies, Siemens Healthineers World expert in medical imaging physics Former Professor of Radiology, Stanford University Peter G Maxim, PhD Professor & Vice Chair, Radiation Oncology, UC Irvine World expert in medical physics, image-guided radiotherapy Bill Loo MD PhD Professor of Radiation Oncology, Stanford University World expert in lung cancer, stereotactic ablative radiotherapy, FLASH radiobiology Sami Tantawi PhD Professor of Particle Physics & Astrophysics, Stanford University Chief Scientist, Accelerator Technology Research, SLAC National Accelerator Laboratory World expert in accelerator and RF science

Pleased to share that CEO Jeff Amacker has been invited to Keiretsu Forum Mid-Atlantic virtual event tomorrow 4/17 to present TibaRay, Inc and our progress to date. Keiretsu Forum Mid-Atlantic TibaRay is developing a Radiation Therapy device that will Cure Cancer in a FLASH! Having completed the investors due diligence with Keiretsu Forum Midwest and currently raising Series A funds to continue development of Phaser! If interested to know more reach out to CEO @Jeff Amacker! #radiationtherapy #flashRT #curecancer #fundraising #seriesA Sotiris Pagdadis, Ph.D. Howard Lubert https://lnkd.in/dTRUJRXd

Very informative article on FLASH RT by the Oncology Nurse Advisor , and pleased to say TibaRay's PHASER overcomes all challenges mentioned in the article! TibaRay is developing eXactFLASH: Sub-second FLASH treatment Exquisite dose sculpting Anywhere in the body Easy adoption Fits in existing vaults Existing workflow Existing reimbursement codes > 2x patients #radiotherapy #flashrt #oncology #fundraising #SeriesA https://lnkd.in/gn8RSkbJ

Metric
Company Name	TibaRay	Isoray Inc.	Leo Cancer Care	Becton, Dickinson and Company
Symbol				BDX
MSH ID	COM:TIBARAY	COM:FLYWHEELSTAGING:ISORAY	COM:LEOCANCERCARE	COM:BD
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Medical Technology	Medical Devices	Medical Devices	Medical - Instruments & Supplies
Country	US	US	GB	US
Stage
Employee Count	11	51	11	70K
Website	tibaray.com	isoray.flywheelstaging.com	leocancercare.com	bd.com
LinkedIn	tibaray-inc		leocancercare	bd1
Founders

Metric
Market Cap			64.70B
Enterprise Value
Monthly Web Traffic	49	2.42K
Web Traffic Growth		-0.70
Valuation
Raised Capital

Metric
Revenue				20.18B
Revenue (LTM)
Revenue (NTM)
Gross Profit				20.18B
EBITDA				2.42B
Operating Income				2.42B
Net Income				1.73B
EPS				5.96
Diluted EPS				5.93
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.55
Operating Profit Margin				0.12
EBITDA Margin				0.12
Net Profit Margin				0.07
Return on Equity				0.06
Return on Assets				0.03
Return on Capital Employed				0.05

COM:TIBARAY

TibaRay

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				54.49
P/B Ratio				2.70
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				3.63
EV Multiple				15.21

Metric
Days Sales Outstanding				42.45
Days Payables Outstanding
Days Inventory Outstanding				105.52
Operating Cycle				151.20
Cash Conversion Cycle				47.37
Asset Turnover				0.37

Metric
Operating Cash Flow				3.84B
Free Cash Flow				3.12B
Cash Flow to Debt				0.21
Operating Cash Flow/Sales				0.20
Free Cash Flow Yield				0.04

Metric
Cash & Equivalents				1.86B
Accounts Receivable
Inventory				3.84B
Goodwill				26.46B
Debt to Capitalization				0.43
Debt to Assets				0.33
Current Ratio				1.08
Quick Ratio				1.36

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.01
R&D to Revenue				0.06
SG&A to Revenue